The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.
 
Saeed Dabestani
No Relationships to Disclose
 
Christian Beisland
No Relationships to Disclose
 
Grant Stewart
Research Funding - AstraZeneca (Inst)
 
Umberto Capitanio
No Relationships to Disclose
 
Petrus Jarvinen
No Relationships to Disclose
 
Harry Nisen
No Relationships to Disclose
 
Karim Bensalah
No Relationships to Disclose
 
Eirikur Guðmundsson
Travel, Accommodations, Expenses - Bayer
 
Thomas B Lam
No Relationships to Disclose
 
Lorenzo Marconi
No Relationships to Disclose
 
Sergio Fernandèz-Pello
No Relationships to Disclose
 
Serenella Monagas
No Relationships to Disclose
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Richard Paul Meijer
No Relationships to Disclose
 
Alessandro Volpe
No Relationships to Disclose
 
Michael D. Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Incyte; Ipsen; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
 
Borje Ljungberg
No Relationships to Disclose
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)